GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] split one vial across Janoshik and Medutest — 99.2% and 96.2% — 28 comments in the full submission. View in context.
5.6k
c/tirzepatide·submitted 3 months ago by u/kaia_wojcik

[Lab] split one vial across Janoshik and Medutest — 99.2% and 96.2%

Labbranch of 7 comments

split one vial across Janoshik and Medutest — 99.2% and 96.2%. One vial, one service, one member paying, which is the only kind of result this board should treat as evidence. 99.2% and 96.2% — those are the numbers, and they are the ones I am willing to defend. SURMOUNT-1 ran 72 weeks with the top arm around 21% mean…

Read the full submission and all 28 comments →

This branch

7 comments, started 3 months ago
u/amara_halonen0 points·3 months ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
u/kaia_wojcikOP1 point·3 months ago·edited

Research-use-only material is not approved for human use.

amara_halonen is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

replysharereportpermalink
u/sanne_novak1 point·3 months ago

Which week did the appetite change actually land for you?

replysharereportpermalink
u/forest_plot_fionastats1 point·3 months ago

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

replysharereportpermalink
u/mikkel_kimani1 point·3 months ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/adnan_nascimento1 point·3 months ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

replysharereportpermalink
u/ingrid_correia1 point·3 months ago·edited

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.